Turkiye Klinikleri Journal of Veterinary Sciences

.: REVIEW
Geleneksel Derleme: Enterokolitislerde Bağırsak Biyobelirteçlerinin Teşhisteki Önemi
Traditional Review: The Importance of Intestinal Biomarkers in Diagnosis in Enterocolitis
Murat Kaan DURGUTa, Mahmut OKa
aKonya Selçuk Üniversitesi Veteriner Fakültesi, İç Hastalıkları ABD, Konya, Türkiye
Turkiye Klinikleri J Vet Sci. 2022;13(1):11-9
doi: 10.5336/vetsci.2020-79135
Article Language: TR
Full Text
ÖZET
 Bağırsaklar, besinlerin sindirimi ve emilimi ile birlikte canlıları çevresel tehditlere karşı koruyan bir immünolojik organ özelliğine sahiptir. Enterokolitis, ince bağırsakların yangısı olan enteritis ve kolonun yangısı olan kolitisi içeren sindirim kanalının yangısı olarak tanımlanmaktadır. Bakteriyel, viral, protozoal, fungal, paraziter etkenlere ve diğer nedenlere bağlı oluşan bu durum önemli derecede su, besin ve mineral kayıpları ile seyredebilmektedir. Enterokolitislerin seyri sırasında bağırsaklarda gelişen villus hasarı, epitel yüzeyinde azalma, sindirim ve emilim kapasitesinin önemli derecede azalmasına neden olmakta ve bu hasarın şiddetinin belirlenmesi gerektiğinde sıklıkla geleneksel invaziv metotlara ihtiyaç duyulmaktadır. Bu pratik olmayan metotlar, günümüzde yerini hastalığın şiddetini, varlığını ve seyrini gösterebilen kanda bulunan proteinlerin ölçülmesi olarak tanımlanabilen biyobelirteçlere bırakmaya başlamış, son yıllarda hem beşerî hem veteriner hekimlikte çalışma konusu olmuştur. Yapılan çalışmalar, biyobelirteçlerin kan ve idrardaki salınım miktarının, çeşitli bağırsak hastalıklarının seyri esnasında değişiklik gösterdiğini ortaya koymaktadır. Bununla birlikte bazı biyobelirteçlerin, bağırsaklar üzerinde koruyucu etkilerinin de olduğu bildirilmektedir. Bu derlemede, bağırsak ile ilgili biyobelirteçler arasından seçilen yağ asidi bağlayıcı proteinler, trefoil faktör 3, intestinal alkalin fosfataz, klaudinler, bağırsak düz kas aktini, platelet aktive edici faktör, leptin ve interlökin 8 ve bu biyobelirteçlerin; enterokolitislerde değerlendirilmesi, teşhisteki kullanımları, veteriner hekimlik için önemi hakkında yeni ve güncel bilgiler sunulması amaçlanmıştır.

Anahtar Kelimeler: Enterokolitis; teşhis; bağırsak biyobelirteç
ABSTRACT
 As commonly known, the intestines are immunological organ that protects living beings against environmental threats as well as with the properties of digestion and absorption of nutrients. Enterocolitis is defined as the inflammation of the digestive tract, including enteritis that is the inflammation of the small intestines and also colitis that is the inflammation of the colon. This condition, which occurs due to bacterial, viral, protozoal, fungal, parasitic factors and other causes, may progress with significant water, nutrient and mineral losses. During the progress of enterocolitis, the villus damage that develops in the intestines and the reduction in the epithelial surface cause a prominent decrease in the digestion and absorption capacity, and to determine the severity of the damage conventional invasive methods are often required. These impractical methods have begun to be replaced by biomarkers which have been the subject of both human and veterinary medicine in recent years that can be defined as the measurement of proteins in blood that can indicate the severity, presence and progress of the disease. Studies show that the amount of released biomarkers into blood and urine varies during the course of diverse bowel diseases. However, some biomarkers are reported to have protective effects on the intestines. In this review, it was aimed to present new and updated information about selected intestinal-related biomarkers such as fatty acid binding proteins, trefoil factor 3, intestinal alkaline phosphatase, claudins, intestinal smooth muscle actin, platelet activating factor, leptin and interleukin 8 and the evaluation of these biomarkers in enterocolitis, their use in diagnosis, and their importance for veterinary medicine.

Keywords: Enterocolitis; diagnosis; intestinal biomarker
REFERENCES:
  1. Turgut K, Ok M. Kedi ve Köpek Gastroenterolojisi. 1. Baskı. Konya: Bahçıvanlar Basımevi; 2001. p.283-421.
  2. Lu Z, Ding L, Lu Q, Chen YH. Claudins in intestines: Distribution and functional significance in health and diseases. Tissue Barriers. 2013;1(3):e24978. [Crossref]  [PubMed]  [PMC] 
  3. Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov. 2008;7(6):489-503. [Crossref]  [PubMed]  [PMC] 
  4. Ok M, Yildiz R, Hatipoglu F, Baspinar N, Ider M, Üney K, et al. Use of intestine-related biomarkers for detecting intestinal epithelial damage in neonatal calves with diarrhea. Am J Vet Res. 2020;81(2):139-46. [Crossref]  [PubMed] 
  5. Yildiz R, Ok M, Ider M, Aydogdu U, Naseri A, Parlak K, et al. Evaluation of intestinal damage biomarkers in calves with atresia coli. J Vet Res. 2018;62(3):379-84. [Crossref]  [PubMed]  [PMC] 
  6. Yildiz R, Ok M, Ider M, Akar A, Naseri A, Koral E. The changes in biomarkers for necrotising enterocolitis in premature calves with respiratory distress syndrome. Vet Med (Praha). 2019;64(10):440-7. [Crossref] 
  7. Ettinger SJ, Edward CF, Cote E. Textbook of Veterinary Internal Medicine. In: Hall JE, Day MJ. Small Intestine Diseases. 8th ed. Missouri: Elsevier; 2018. p.3643-820.
  8. Ng EW, Poon TC, Lam HS, Cheung HM, Ma TP, Chan KY, et al. Gut-associated biomarkers L-FABP, I-FABP, and TFF3 and LIT score for diagnosis of surgical necrotizing enterocolitis in preterm infants. Ann Surg. 2013;258(6):1111-8. [Crossref]  [PubMed] 
  9. Arisanti D, Wibowo S, Soemarno S. Calprotectin and intestinal fatty acid binding protein (I-FABP) level in preterm neonates with necrotizing enterocolitis. Res J Biol Sci. 2019;6(1):1-10. [Crossref] 
  10. Thuijls G, Derikx JP, van Wijck K, Zimmermann LJ, Degraeuwe PL, Mulder TL, et al. Non-invasive markers for early diagnosis and determination of the severity of necrotizing enterocolitis. Ann Surg. 2010;251(6):1174-80. [Crossref]  [PubMed] 
  11. Molnár K, Vannay A, Szebeni B, Bánki NF, Sziksz E, Cseh A, et al. Intestinal alkaline phosphatase in the colonic mucosa of children with inflammatory bowel disease. World J Gastroenterol. 2012;18(25):3254-9. [PubMed]  [PMC] 
  12. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001;414(6865):799-806. [Crossref]  [PubMed] 
  13. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860-7. [Crossref]  [PubMed] 
  14. Ockner RK, Manning JA, Poppenhausen RB, Ho WK. A binding protein for fatty acids in cytosol of intestinal mucosa, liver, myocardium, and other tissues. Science. 1972;177(4043):56-8. [Crossref]  [PubMed] 
  15. Veerkamp JH, van Moerkerk HT. Fatty acid-binding protein and its relation to fatty acid oxidation. In: Glatz JFC, van der Vusse GJ, eds. Cellular Fatty Acid-Binding Proteins II. 1st ed. Boston: Springer; 1993. p.101-6. [Crossref]  [PubMed] 
  16. Tuğlu B, Uysal S. Yağ asidi bağlayıcı proteinler [Fatty acid binding proteins]. Turk J Biochem. 2011;9(1):31-8. [Link] 
  17. Gollin G, Marks C, Marks WH. Intestinal fatty acid binding protein in serum and urine reflects early ischemic injury to the small bowel. Surgery. 1993;113(5):545-51. [PubMed] 
  18. Pelsers MM, Namiot Z, Kisielewski W, Namiot A, Januszkiewicz M, Hermens WT, et al. Intestinal-type and liver-type fatty acid-binding protein in the intestine. Tissue distribution and clinical utility. Clin Biochem. 2003;36(7):529-35. [Crossref]  [PubMed] 
  19. Thuijls G, Derikx JP, de Haan JJ, Grootjans J, de Bruïne A, Masclee AA, et al. Urine-based detection of intestinal tight junction loss. J Clin Gastroenterol. 2010;44(1):e14-9. [Crossref]  [PubMed] 
  20. Thim L. Trefoil peptides: a new family of gastrointestinal molecules. Digestion. 1994;55(6):353-60. [Crossref]  [PubMed] 
  21. Emami S, Rodrigues S, Rodrigue CM, Le Floch N, Rivat C, Attoub S, et al. Trefoil factor family (TFF) peptides and cancer progression. Peptides. 2004;25(5):885-98. [Crossref]  [PubMed] 
  22. Tran CP, Cook GA, Yeomans ND, Thim L, Giraud AS. Trefoil peptide TFF2 (spasmolytic polypeptide) potently accelerates healing and reduces inflammation in a rat model of colitis. Gut. 1999;44(5):636-42. [Crossref]  [PubMed]  [PMC] 
  23. Lin J, Holzman IR, Jiang P, Babyatsky MW. Expression of intestinal trefoil factor in developing rat intestine. Biol Neonate. 1999;76(2):92-7. [Crossref]  [PubMed] 
  24. Furuta GT, Turner JR, Taylor CT, Hershberg RM, Comerford K, Narravula S, et al. Hypoxia-inducible factor 1-dependent induction of intestinal trefoil factor protects barrier function during hypoxia. J Exp Med. 2001;193(9):1027-34. [Crossref]  [PubMed]  [PMC] 
  25. Yang Y, Wandler AM, Postlethwait JH, Guillemin K. Dynamic evolution of the LPS-detoxifying enzyme intestinal alkaline phosphatase in zebrafish and other vertebrates. Front Immunol. 2012;3:314. [Crossref]  [PubMed]  [PMC] 
  26. Malo MS, Moaven O, Muhammad N, Biswas B, Alam SN, Economopoulos KP, et al. Intestinal alkaline phosphatase promotes gut bacterial growth by reducing the concentration of luminal nucleotide triphosphates. Am J Physiol Gastrointest Liver Physiol. 2014;306(10):G826-38. [Crossref]  [PubMed]  [PMC] 
  27. Martínez-Moya P, Ortega-González M, González R, Anzola A, Ocón B, Hernández-Chirlaque C, et al. Exogenous alkaline phosphatase treatment complements endogenous enzyme protection in colonic inflammation and reduces bacterial translocation in rats. Pharmacol Res. 2012;66(2):144-53. [Crossref]  [PubMed] 
  28. Lallès JP. Intestinal alkaline phosphatase: multiple biological roles in maintenance of intestinal homeostasis and modulation by diet. Nutr Rev. 2010;68(6):323-32. [Crossref]  [PubMed] 
  29. Fawley J, Gourlay DM. Intestinal alkaline phosphatase: a summary of its role in clinical disease. J Surg Res. 2016;202(1):225-34. [Crossref]  [PubMed]  [PMC] 
  30. Janssens S, Beyaert R. Role of Toll-like receptors in pathogen recognition. Clin Microbiol Rev. 2003;16(4):637-46. [Crossref]  [PubMed]  [PMC] 
  31. Estaki M, DeCoffe D, Gibson DL. Interplay between intestinal alkaline phosphatase, diet, gut microbes and immunity. World J Gastroenterol. 2014;20(42):15650-6. [Crossref]  [PubMed]  [PMC] 
  32. Rietschel ET, Kirikae T, Schade FU, Mamat U, Schmidt G, Loppnow H, et al. Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB J. 1994;8(2):217-25. [Crossref]  [PubMed] 
  33. Bentala H, Verweij WR, Huizinga-Van der Vlag A, van Loenen-Weemaes AM, Meijer DK, Poelstra K. Removal of phosphate from lipid A as a strategy to detoxify lipopolysaccharide. Shock. 2002;18(6):561-6. [Crossref]  [PubMed] 
  34. Tuin A, Poelstra K, de Jager-Krikken A, Bok L, Raaben W, Velders MP, et al. Role of alkaline phosphatase in colitis in man and rats. Gut. 2009;58(3):379-87. [Crossref]  [PubMed] 
  35. Riggle KM, Rentea RM, Welak SR, Pritchard KA Jr, Oldham KT, Gourlay DM. Intestinal alkaline phosphatase prevents the systemic inflammatory response associated with necrotizing enterocolitis. J Surg Res. 2013;180(1):21-6. [Crossref]  [PubMed]  [PMC] 
  36. Koyama I, Matsunaga T, Harada T, Hokari S, Komoda T. Alkaline phosphatases reduce toxicity of lipopolysaccharides in vivo and in vitro through dephosphorylation. Clin Biochem. 2002;35(6):455-61. [Crossref]  [PubMed] 
  37. Goldberg RF, Austen WG Jr, Zhang X, Munene G, Mostafa G, Biswas S, et al. Intestinal alkaline phosphatase is a gut mucosal defense factor maintained by enteral nutrition. Proc Natl Acad Sci U S A. 2008;105(9):3551-6. [Crossref]  [PubMed]  [PMC] 
  38. Laukoetter MG, Bruewer M, Nusrat A. Regulation of the intestinal epithelial barrier by the apical junctional complex. Curr Opin Gastroenterol. 2006;22(2):85-9. [Crossref]  [PubMed] 
  39. Turksen K, Troy TC. Barriers built on claudins. J Cell Sci. 2004;117(Pt 12):2435-47. Erratum in: J Cell Sci. 2004;117(Pt 18):4341. [Crossref]  [PubMed] 
  40. Van Itallie CM, Anderson JM. Claudins and epithelial paracellular transport. Annu Rev Physiol. 2006;68:403-29. [Crossref]  [PubMed] 
  41. Lal-Nag M, Morin PJ. The claudins. Genome Biol. 2009;10(8):235. [Crossref]  [PubMed]  [PMC] 
  42. Lameris AL, Huybers S, Kaukinen K, Mäkelä TH, Bindels RJ, Hoenderop JG, et al. Expression profiling of claudins in the human gastrointestinal tract in health and during inflammatory bowel disease. Scand J Gastroenterol. 2013;48(1):58-69. [Crossref]  [PubMed] 
  43. Patel RM, Myers LS, Kurundkar AR, Maheshwari A, Nusrat A, Lin PW. Probiotic bacteria induce maturation of intestinal claudin 3 expression and barrier function. Am J Pathol. 2012;180(2):626-35. Erratum in: Am J Pathol. 2012;180(3):1324. [Crossref]  [PubMed]  [PMC] 
  44. Karaki S, Kaji I, Otomo Y, Tazoe H, Kuwahara A. The tight junction component protein, claudin-4, is expressed by enteric neurons in the rat distal colon. Neurosci Lett. 2007;428(2-3):88-92. [Crossref]  [PubMed] 
  45. Ohta H, Yamaguchi T, Rajapakshage BK, Murakami M, Sasaki N, Nakamura K, et al. Expression and subcellular localization of apical junction proteins in canine duodenal and colonic mucosa. Am J Vet Res. 2011;72(8):1046-51. [Crossref]  [PubMed] 
  46. Ding L, Lu Z, Foreman O, Tatum R, Lu Q, Renegar R, et al. Inflammation and disruption of the mucosal architecture in claudin-7-deficient mice. Gastroenterology. 2012;142(2):305-15. [Crossref]  [PubMed]  [PMC] 
  47. Tamura A, Kitano Y, Hata M, Katsuno T, Moriwaki K, Sasaki H, et al. Megaintestine in claudin-15-deficient mice. Gastroenterology. 2008;134(2):523-34. [Crossref]  [PubMed] 
  48. Tamura A, Hayashi H, Imasato M, Yamazaki Y, Hagiwara A, Wada M, et al. Loss of claudin-15, but not claudin-2, causes Na+ deficiency and glucose malabsorption in mouse small intestine. Gastroenterology. 2011;140(3):913-23. [Crossref]  [PubMed] 
  49. Ivanov AI, Nusrat A, Parkos CA. The epithelium in inflammatory bowel disease: potential role of endocytosis of junctional proteins in barrier disruption. Novartis Found Symp. 2004;263:115-24; discussion 124-32, 211-8. [Crossref]  [PubMed] 
  50. Zeissig S, Bürgel N, Günzel D, Richter J, Mankertz J, Wahnschaffe U, et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut. 2007;56(1):61-72. [Crossref]  [PubMed]  [PMC] 
  51. Mennigen R, Nolte K, Rijcken E, Utech M, Loeffler B, Senninger N, et al. Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol. 2009;296(5):G1140-9. [Crossref]  [PubMed] 
  52. Szakál DN, Gyorffy H, Arató A, Cseh A, Molnár K, Papp M, et al. Mucosal expression of claudins 2, 3 and 4 in proximal and distal part of duodenum in children with coeliac disease. Virchows Arch. 2010;456(3):245-50. [Crossref]  [PubMed] 
  53. Lattanzi G, Cenni V, Marmiroli S, Capanni C, Mattioli E, Merlini L, et al. Association of emerin with nuclear and cytoplasmic actin is regulated in differentiating myoblasts. Biochem Biophys Res Commun. 2003;303(3):764-70. [Crossref]  [PubMed] 
  54. Evennett N, Cerigioni E, Hall NJ, Pierro A, Eaton S. Smooth muscle actin as a novel serologic marker of severe intestinal damage in rat intestinal ischemia-reperfusion and human necrotising enterocolitis. J Surg Res. 2014;191(2):323-30. [Crossref]  [PubMed] 
  55. Englberger W, Bitter-Suermann D, Hadding U. Influence of lysophospholipids and PAF on the oxidative burst of PMNL. Int J Immunopharmacol. 1987;9(3):275-82. [Crossref]  [PubMed] 
  56. MacKendrick W, Hill N, Hsueh W, Caplan M. Increase in plasma platelet-activating factor levels in enterally fed preterm infants. Biol Neonate. 1993;64(2-3):89-95. [Crossref]  [PubMed] 
  57. Caplan MS, Sun XM, Hseuh W, Hageman JR. Role of platelet activating factor and tumor necrosis factor-alpha in neonatal necrotizing enterocolitis. J Pediatr. 1990;116(6):960-4. [Crossref]  [PubMed] 
  58. Zimmerman BJ, Granger DN. Reperfusion injury. Surg Clin North Am. 1992;72(1):65-83. [Crossref]  [PubMed] 
  59. Caplan MS, Adler L, Kelly A, Hsueh W. Hypoxia increases stimulus-induced PAF production and release from human umbilical vein endothelial cells. Biochim Biophys Acta. 1992;1128(2-3):205-10. [Crossref]  [PubMed] 
  60. Martin CR, Walker WA. Intestinal immune defences and the inflammatory response in necrotising enterocolitis. Semin Fetal Neonatal Med. 2006;11(5):369-77. [Crossref]  [PubMed] 
  61. Yıldız R, Beslek M, Beydilli Y, Özçelik MM, Biçici Ö. Evaluation of platelet activating factor in neonatal calves with sepsis. Vet Hekim Der Derg. 2018;89(2):66-73. [Link] 
  62. Baggiolini M, Walz A, Kunkel SL. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest. 1989;84(4):1045-9. [Crossref]  [PubMed]  [PMC] 
  63. Neu J. Neonatal necrotizing enterocolitis: an update. Acta Paediatr Suppl. 2005;94(449):100-5. [Crossref]  [PubMed] 
  64. Mukaida N, Shiroo M, Matsushima K. Genomic structure of the human monocyte-derived neutrophil chemotactic factor IL-8. J Immunol. 1989;143(4):1366-71. [PubMed] 
  65. Daig R, Andus T, Aschenbrenner E, Falk W, Schölmerich J, Gross V. Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease. Gut. 1996;38(2):216-22. [Crossref]  [PubMed]  [PMC] 
  66. Benkoe TM, Mechtler TP, Weninger M, Pones M, Rebhandl W, Kasper DC. Serum levels of interleukin-8 and gut-associated biomarkers in diagnosing necrotizing enterocolitis in preterm infants. J Pediatr Surg. 2014;49(10):1446-51. [Crossref]  [PubMed] 
  67. Özkan KU, İnanç F, Kılınç M, Boran Ç. Leptin tedavisi yeni doğan rat incebarsağında hipoksi/reoksijenasyon hasarına karşı koruyucu mudur? [Effect of leptin treatment on small intestinal damage induced by hypoxia reoxygenation in newborn rats]. Fırat Tıp Dergisi. 2005;10(1):5-9. [Link] 
  68. Gaigé S, Abysique A, Bouvier M. Effects of leptin on cat intestinal motility. J Physiol. 2003;546(Pt 1):267-77. [Crossref]  [PubMed]  [PMC] 
  69. Saleri R, Giustina A, Tamanini C, Valle D, Burattin A, Wehrenberg WB, et al. Leptin stimulates growth hormone secretion via a direct pituitary effect combined with a decreased somatostatin tone in a median eminence-pituitary perifusion study. Neuroendocrinology. 2004;79(4):221-8. [Crossref]  [PubMed] 
  70. Liu DR, Xu XJ, Yao SK. Increased intestinal mucosal leptin levels in patients with diarrhea-predominant irritable bowel syndrome. World J Gastroenterol. 2018;24(1):46-57. [Crossref]  [PubMed]  [PMC] 

.: Up To Date

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com